UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1‐infected patients without cirrhosis: OPTIMIST‐1, a phase 3, randomized study

Hepatology (Baltimore, Md.), 2016-08, Vol.64 (2), p.370-380

2016

Volltextzugriff (PDF)

Lumicitabine, an orally administered nucleoside analog, in infants hospitalized with respiratory syncytial virus (RSV) infection: Safety, efficacy, and pharmacokinetic results

PloS one, 2023-07, Vol.18 (7), p.e0288271-e0288271

2023

Volltextzugriff (PDF)

Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region

Antiviral research, 2015-04, Vol.116, p.10-16

2015

Volltextzugriff (PDF)

Risk factors predictive of anemia development during telaprevir plus peginterferon/ribavirin therapy in treatment-experienced patients

Journal of hepatology, 2014-06, Vol.60 (6), p.1112-1117

2014

Volltextzugriff (PDF)

Pharmacokinetic Interaction between Telaprevir and Methadone

Antimicrobial Agents and Chemotherapy, 2013-05, Vol.57 (5), p.2304-2309

2013

Volltextzugriff (PDF)

Efficacy of telaprevir-based therapy in stable liver transplant patients with chronic genotype 1 hepatitis C

Annals of hepatology, 2016-07, Vol.15 (4), p.512-523

2016

Volltextzugriff (PDF)

Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST‐2)

Hepatology (Baltimore, Md.), 2016-08, Vol.64 (2), p.360-369

2016

Volltextzugriff (PDF)

IL‐15 enhances the function and inhibits CD95/Fas‐induced apoptosis of human CD4+ and CD8+ effector‐memory T cells

International immunology, 2003-01, Vol.15 (1), p.49-58

2003

Volltextzugriff (PDF)

The Hospital Recovery Scale: A clinically useful endpoint in patients hospitalized with influenza

Contemporary clinical trials, 2022-12, Vol.123, p.106952-106952, Article 106952

2022

Volltextzugriff (PDF)

Measuring respiratory syncytial virus infection severity in hospitalized children using the Pediatric Respiratory Syncytial Virus Electronic Severity and Outcome Rating System (PRESORS)

Influenza and other respiratory viruses, 2022-11, Vol.16 (6), p.1091-1100

2022

Volltextzugriff (PDF)

Lumicitabine, an orally administered nucleoside analog, in infants hospitalized with respiratory syncytial virus

PloS one, 2023-07, Vol.18 (7), p.e0288271

2023

Volltextzugriff (PDF)

Freesia Study Design: JNJ-53718678 in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Upper Respiratory Tract

Blood, 2019-11, Vol.134 (Supplement_1), p.4478-4478

2019

Volltextzugriff (PDF)

Comparative assessment of reported symptoms of influenza, respiratory syncytial virus, and human metapneumovirus infection during hospitalization and post‐discharge assessed by Respiratory Intensity and Impact Questionnaire

Influenza and other respiratory viruses, 2022-01, Vol.16 (1), p.79-89

2022

Volltextzugriff (PDF)

Risk Factors and Medical Resource Utilization of Respiratory Syncytial Virus, Human Metapneumovirus, and Influenza-Related Hospitalizations in Adults—A Global Study During the 2017–2019 Epidemic Seasons (Hospitalized Acute Respiratory Tract Infection [HARTI] Study)

Open forum infectious diseases, 2021-11, Vol.8 (11), p.ofab491-ofab491

2021

Volltextzugriff (PDF)

Efficacy and safety outcomes among treatment-experienced women and men treated with etravirine in gender, race and clinical experience

AIDS research and human retroviruses, 2012-06, Vol.28 (6), p.544-551

2012

Volltextzugriff (PDF)

Pharmacokinetic parameters of once―daily rilpivirine following administration of efavirenz in healthy subjects

Antiviral therapy, 2012-01, Vol.17 (3), p.439-446

2012

Volltextzugriff (PDF)

An OPTIMIZE study retrospective analysis for management of telaprevir-treated hepatitis C virus (HCV)-infected patients by use of the Abbott RealTime HCV RNA assay

Journal of clinical microbiology, 2015-04, Vol.53 (4), p.1264-1269

2015

Volltextzugriff (PDF)

Featured Cover

Influenza and other respiratory viruses, 2022-01, Vol.16 (1), p.i-i

2022

Volltextzugriff (PDF)

Telaprevir Twice Daily Is Noninferior to Telaprevir Every 8 Hours for Patients With Chronic Hepatitis C

Gastroenterology (New York, N.Y. 1943), 2014-03, Vol.146 (3), p.744-753.e3

2014

Volltextzugriff (PDF)

Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials

Antiviral therapy, 2010-01, Vol.15 (7), p.1045-1052

2010

Volltextzugriff (PDF)

Evolution of hepatitis C virus quasispecies during repeated treatment with the NS3/4A protease inhibitor telaprevir

Antimicrobial agents and chemotherapy, 2015-05, Vol.59 (5), p.2746-2755

2015

Volltextzugriff (PDF)

An OPTIMIZE Study Retrospective Analysis for Management of Telaprevir-Treated Hepatitis C Virus (HCV)-Infected Patients by Use of the Abbott RealTi m e HCV RNA Assay

Journal of clinical microbiology, 2015-04, Vol.53 (4), p.1264-1269

2015

Volltextzugriff (PDF)

Pharmacokinetics of bound and unbound telaprevir in cirrhotic patients with moderate and severe hepatic impairment

Journal of clinical pharmacology, 2015-10, Vol.55 (10), p.1147-1156

2015

Volltextzugriff (PDF)

Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial

Hepatology (Baltimore, Md.), 2013-12, Vol.58 (6), p.1897-1906

2013

Volltextzugriff (PDF)

Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-naïve patients in China and South Korea

Journal of gastroenterology and hepatology, 2016-05, Vol.31 (5), p.912-920

2016

Volltextzugriff (PDF)

1 – 25 von 139

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(123)
Mit Volltextzugriff
(112)

Publikationsform

Sprache

Englisch
(137)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1‐infected patients without cirrhosis: OPTIMIST‐1, a phase 3, randomized study

Lumicitabine, an orally administered nucleoside analog, in infants hospitalized with respiratory syncytial virus (RSV) infection: Safety, efficacy, and pharmacokinetic results

Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region

Risk factors predictive of anemia development during telaprevir plus peginterferon/ribavirin therapy in treatment-experienced patients

Pharmacokinetic Interaction between Telaprevir and Methadone

Efficacy of telaprevir-based therapy in stable liver transplant patients with chronic genotype 1 hepatitis C

Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST‐2)

IL‐15 enhances the function and inhibits CD95/Fas‐induced apoptosis of human CD4+ and CD8+ effector‐memory T cells

The Hospital Recovery Scale: A clinically useful endpoint in patients hospitalized with influenza

Measuring respiratory syncytial virus infection severity in hospitalized children using the Pediatric Respiratory Syncytial Virus Electronic Severity and Outcome Rating System (PRESORS)

Lumicitabine, an orally administered nucleoside analog, in infants hospitalized with respiratory syncytial virus

Freesia Study Design: JNJ-53718678 in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Upper Respiratory Tract

Comparative assessment of reported symptoms of influenza, respiratory syncytial virus, and human metapneumovirus infection during hospitalization and post‐discharge assessed by Respiratory Intensity and Impact Questionnaire

Risk Factors and Medical Resource Utilization of Respiratory Syncytial Virus, Human Metapneumovirus, and Influenza-Related Hospitalizations in Adults—A Global Study During the 2017–2019 Epidemic Seasons (Hospitalized Acute Respiratory Tract Infection [HARTI] Study)

Efficacy and safety outcomes among treatment-experienced women and men treated with etravirine in gender, race and clinical experience

Pharmacokinetic parameters of once―daily rilpivirine following administration of efavirenz in healthy subjects

An OPTIMIZE study retrospective analysis for management of telaprevir-treated hepatitis C virus (HCV)-infected patients by use of the Abbott RealTime HCV RNA assay

Featured Cover

Telaprevir Twice Daily Is Noninferior to Telaprevir Every 8 Hours for Patients With Chronic Hepatitis C

Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials

Evolution of hepatitis C virus quasispecies during repeated treatment with the NS3/4A protease inhibitor telaprevir

An OPTIMIZE Study Retrospective Analysis for Management of Telaprevir-Treated Hepatitis C Virus (HCV)-Infected Patients by Use of the Abbott RealTi m e HCV RNA Assay

Pharmacokinetics of bound and unbound telaprevir in cirrhotic patients with moderate and severe hepatic impairment

Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial

Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-naïve patients in China and South Korea

Suchergebnisse filtern